Immune-mediated glomerular diseases: new basic concepts and clinical implications

被引：6
|
作者：
Panzer, Ulf [1 ,2 ,3 ]
Huber, Tobias B. [1 ,3 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Dept Med 3, Martinistr 52, D-20246 Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Dept Med 3, Div Translat Immunol, Hamburg, Germany
[3] Univ Med Ctr Hamburg Eppendorf, Hamburg Ctr Translat Immunol HCTI, Hamburg, Germany
来源：
CELL AND TISSUE RESEARCH | 2021年 / 385卷 / 02期
关键词：
D O I：
10.1007/s00441-021-03509-5
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：277 / 279
页数：3
相关论文
共 50 条
  • [21] Advantages and shortcomings of experimental models of immune-mediated glomerular and tubulointerstitial diseases
    DeHeer, E
    Bruijn, JA
    EXPERIMENTAL NEPHROLOGY, 1996, 4 (04): : 193 - 200
  • [22] Direct Effects of Immunomodulatory Agents on Podocytes in Immune-Mediated Glomerular Diseases
    Manabe, Shun
    Nitta, Kosaku
    Nagata, Michio
    RECENT ADVANCES IN THE PATHOGENESIS AND TREATMENT OF KIDNEY DISEASES, 2018, 195 : 131 - 142
  • [23] Biomarkers of tolerance in immune-mediated inflammatory diseases: a new era in clinical management?
    Baker, Kenneth F.
    Sim, Jasmine P. X.
    Isaacs, John D.
    LANCET RHEUMATOLOGY, 2021, 3 (05): : E371 - E382
  • [24] T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy
    Gao, Zhanyan
    Feng, Yang
    Xu, Jinhua
    Liang, Jun
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [25] Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety
    Milena A. Gianfrancesco
    Gabriela Schmajuk
    Sarah Haserodt
    Laura Trupin
    Zara Izadi
    Kashif Jafri
    Stephen Shiboski
    Marina Sirota
    R. Adams Dudley
    Jinoos Yazdany
    Rheumatology International, 2017, 37 : 1611 - 1618
  • [26] Implications of NKG2A in immunity and immune-mediated diseases
    Wang, Xiaotong
    Xiong, Huabao
    Ning, Zhaochen
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [27] Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety
    Gianfrancesco, Milena A.
    Schmajuk, Gabriela
    Haserodt, Sarah
    Trupin, Laura
    Izadi, Zara
    Jafri, Kashif
    Shiboski, Stephen
    Sirota, Marina
    Dudley, R. Adams
    Yazdany, Jinoos
    RHEUMATOLOGY INTERNATIONAL, 2017, 37 (10) : 1611 - 1618
  • [28] Novel B Cell Therapeutic Targets in Transplantation and Immune-Mediated Glomerular Diseases
    Vincenti, Flavio
    Cohen, Scott D.
    Appel, Gerald
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (01): : 142 - 151
  • [29] Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases
    Kattah, Andrea G.
    Fervenza, Fernando C.
    Roccatello, Dario
    AUTOIMMUNITY REVIEWS, 2013, 12 (08) : 854 - 859
  • [30] COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases
    Gauckler, Philipp
    Kesenheimer, Jana S.
    Geetha, Duvuru
    Odler, Balazs
    Eller, Kathrin
    Laboux, Timothee
    Alberici, Federico
    Zappa, Mattia
    Chebotareva, Natasha
    Moiseev, Sergey
    Bonilla, Marco
    Jhaveri, Kenar D.
    Oniszczuk, Julie
    Audard, Vincent
    Costa, Denise
    Mastroianni-Kirsztajn, Gianna
    Bruchfeld, Annette
    Muto, Masahiro
    Windpessl, Martin
    Mayer, Gert
    Kronbichler, Andreas
    FRONTIERS IN IMMUNOLOGY, 2023, 14
12345